FLAG ± IDA regimen for children with relapsed/refractory acute leukaemia shows high toxicity
Use of fludarabine cytarabine and granulocyte colony stimulating factor with or without idarubicin (FLAG ± IDA) leads to a 69-percent rate of complete remission in children with relapsed/refractory acute leukaemia, but only 48 percent of patients survive to bone marrow transplantation, a study has shown.